Advertisement
Platinum Priority – Editorial and Reply from Authors Referring to the article published on pp. 1–7 of this issue| Volume 58, ISSUE 1, P8-9, July 01, 2010

Defining and Treating High-Risk Prostate Cancer: Can We Do Better?

  • Leah Gerber
    Affiliations
    Duke Prostate Center, Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA

    Department of Surgery, Durham Veterans Administration Hospital, Durham, North Carolina, USA
    Search for articles by this author
  • Lionel L. Bañez
    Affiliations
    Duke Prostate Center, Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA

    Department of Surgery, Durham Veterans Administration Hospital, Durham, North Carolina, USA
    Search for articles by this author
  • Stephen J. Freedland
    Correspondence
    Corresponding author. Division of Urologic Surgery and the Duke Prostate Center, Department of Surgery, Duke University Medical Center, Box 2626, MSRB-I Room 475, 571 Research Drive, Durham, NC 27710, USA. Tel. +1 919 668 8361; Fax: +1 919 668 7093.
    Affiliations
    Duke Prostate Center, Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA

    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

    Department of Surgery, Durham Veterans Administration Hospital, Durham, North Carolina, USA
    Search for articles by this author
      Currently, one in four deaths in both Europe and the United States is the result of cancer. The American Cancer Society identified prostate cancer (PCa) as the most commonly diagnosed non-dermatologic malignancy among American men, and it remains the second most fatal cancer. Similar incidence and mortality figures are reported by the European Association of Urology (EAU).
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to European Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cooperberg M.R.
        • Broering J.M.
        • Carroll P.R.
        Time trends and local variation in primary treatment of localized prostate cancer.
        J Clin Oncol. 2010; 28: 1117-1123
        • D’Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • Spahn M.
        • Joniau S.
        • Gontero P.
        • et al.
        Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
        Eur Urol. 2010; 58: 1-7
        • Nguyen P.L.
        • Chen M.H.
        • Catalona W.J.
        • Moul J.W.
        • Sun L.
        • D’Amico A.V.
        Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
        Int J Radiat Oncol Biol Phys. 2009; 73: 659-664
        • Bastian P.J.
        • Gonzalgo M.L.
        • Aronson W.J.
        • et al.
        Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
        Cancer. 2006; 107: 1265-1272
        • Ward J.F.
        • Slezak J.M.
        • Blute M.L.
        • Bergstralh E.J.
        • Zincke H.
        Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
        BJU Int. 2005; 95: 751-756
        • Freedland S.J.
        • Partin A.W.
        • Humphreys E.B.
        • Mangold L.A.
        • Walsh P.C.
        Radical prostatectomy for clinical stage T3a disease.
        Cancer. 2007; 109: 1273-1278
        • Yossepowitch O.
        • Eggener S.E.
        • Serio A.M.
        • et al.
        Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.
        Eur Urol. 2008; 53: 950-959
        • Albertsen P.C.
        The face of high risk prostate cancer.
        World J Urol. 2008; 26: 205-210
        • Zelefsky M.J.
        • Eastham J.A.
        • Cronin A.M.
        • et al.
        Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.
        J Clin Oncol. 2010; 28: 1508-1513
        • Thompson I.M.
        Defining high risk prostate cancer—where do we set the bar? A translational science approach to risk stratification.
        J Urol. 2006; 176 (discussion S25–26.): S21-S24

      Linked Article